Placebo-Controlled Discontinuation of Long-Term Acid-Suppressant Therapy: A Randomised Trial in General Practice

Jon Eik Zwisler, Dorte Ejg Jarbøl, Annmarie Touborg Lassen, Jakob Kragstrup, Niels Thorsgaard, Ove B Schaffalitzky de Muckadell, Jon Eik Zwisler, Dorte Ejg Jarbøl, Annmarie Touborg Lassen, Jakob Kragstrup, Niels Thorsgaard, Ove B Schaffalitzky de Muckadell

Abstract

Objective. To investigate whether patients on long-term antisecretory medication need to continue treatment to control symptoms. Methods. A double-blinded randomised placebo-controlled trial in general practices in Denmark. Patients aged 18-90 who were treated with antisecretory drugs on a long-term basis were randomized to esomeprazole 40 mg or identical placebo. Outcome measures were time to discontinuation with trial medication due to failed symptom control analysed as survival data. The proportion of patients stopping trial medication during the one-year follow-up was estimated. Results. A total of 171 patients were included with a median prior duration of antisecretory treatment of four years (range: 0.5 to 14.6 years). 86 patients received esomeprazole 40 mg and 85 patients received placebo. At 12 months, statistically significantly more patients in the placebo group had discontinued (73% (62/85)) compared with the esomeprazole group (21% (18/86); p < 0.001). Conclusions. Long-term users of antisecretory drugs showed a preference for the active drug compared to placebo. However, 27% of patients continued on placebo throughout the study and did not need to reinstitute usual treatment. One in five patients treated with esomeprazole discontinued trial medication due to unsatisfactory symptom control. Discontinuation of antisecretory treatment should be considered in long-term users of antisecretory drugs. This trial is registered with Trial registration ClinicalTrials.gov ID: NCT00120315.

Figures

Figure 1
Figure 1
Flow of participants through study.
Figure 2
Figure 2
Discontinuation of trial medication in 1-year follow-up.

References

    1. Haastrup P., Paulsen M. S., Zwisler J. E., et al. Rapidly increasing prescribing of proton pump inhibitors in primary care despite interventions: a nationwide observational study. European Journal of General Practice. 2013;20(4):290–293. doi: 10.3109/13814788.2014.905535.
    1. Lødrup A., Reimer C., Bytzer P. Use of antacids, alginates and proton pump inhibitors: a survey of the general Danish population using an internet panel. Scandinavian Journal of Gastroenterology. 2014;49(9):1044–1050. doi: 10.3109/00365521.2014.923504.
    1. Cahir C., Fahey T., Tilson L., Teljeur C., Bennett K. Proton pump inhibitors: potential cost reductions by applying prescribing guidelines. BMC Health Services Research. 2012;12(1, article 408) doi: 10.1186/1472-6963-12-408.
    1. Lassen A., Hallas J., de Muckadell O. B. S. Use of anti-secretory medication: a population-based cohort study. Alimentary Pharmacology & Therapeutics. 2004;20(5):577–583. doi: 10.1111/j.1365-2036.2004.02120.x.
    1. Raghunath A. S., O'Moraint C., McLoughlin R. C. Review article: the long-term use of proton-pump inhibitors. Alimentary Pharmacology and Therapeutics. 2005;22(1):55–63. doi: 10.1111/j.1365-2036.2005.02611.x.
    1. Moayyedi P., Delaney B. C., Vakil N., Forman D., Talley N. J. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology. 2004;127(5):1329–1337. doi: 10.1053/j.gastro.2004.08.026.
    1. Huang J., Lam S. K., Malfertheiner P., Hunt R. H. Has education about Helicobacter pylori infection been effective? Worldwide survey of primary care physicians. Journal of Gastroenterology and Hepatology. 2003;18(5):512–520. doi: 10.1046/j.1440-1746.2003.03017.x.
    1. Van Zanten S. V., Flook N., Talley N. J., et al. One-week acid suppression trial in uninvestigated dyspepsia patients with epigastric pain or burning to predict response to 8 weeks' treatment with esomeprazole: a randomized, placebo-controlled study. Alimentary Pharmacology & Therapeutics. 2007;26(5):665–672. doi: 10.1111/j.1365-2036.2007.03409.x.
    1. Björnsson E., Abrahamsson H., Simrén M., et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Alimentary Pharmacology and Therapeutics. 2006;24(6):945–954. doi: 10.1111/j.1365-2036.2006.03084.x.
    1. Gandek B., Ware J. E., Jr., Aaronson N. K., et al. Tests of data quality, scaling assumptions, and reliability of the SF-36 in eleven countries: results from the IQOLA Project. Journal of Clinical Epidemiology. 1998;51(11):1149–1158. doi: 10.1016/s0895-4356(98)00106-1.
    1. Revicki D. A., Wood M., Wiklund I., Crawley J. Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease. Quality of Life Research. 1998;7(1):75–83. doi: 10.1023/a:1008841022998.
    1. Bytzer P., Hansen J. M., Schaffalitzky de Muckadell O. B., Malchow-Møller A. Predicting endoscopic diagnosis in the dyspeptic patient. The value of predictive score models. Scandinavian Journal of Gastroenterology. 1997;32(2):118–125. doi: 10.3109/00365529709000181.
    1. Gotzsche P. C. Blinding during data analysis and writing of manuscripts. Controlled Clinical Trials. 1996;17(4):285–293. doi: 10.1016/0197-2456(95)00263-4.
    1. Annual Statistics. Danish Medicines Agency; 2015.
    1. Gaist D., Sørensen H. T., Hallas J. The Danish prescription registries. Danish Medical Bulletin. 1997;44(4):445–448.
    1. Agréus L., Svärdsudd K., Nyrén O., Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology. 1995;109(3):671–680. doi: 10.1016/0016-5085(95)90373-9.
    1. Reimer C., Søndergaard B., Hilsted L., Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137(1):80.e1–87.e1. doi: 10.1053/j.gastro.2009.03.058.
    1. Hunfeld N. G. M., Geus W. P., Kuipers E. J. Systematic review: rebound acid hypersecretion after therapy with proton pump inhibitors. Alimentary Pharmacology and Therapeutics. 2007;25(1):39–46. doi: 10.1111/j.1365-2036.2006.03171.x.
    1. Niklasson A., Lindström L., Simrén M., Lindberg G., Björnsson E. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. American Journal of Gastroenterology. 2010;105(7):1531–1537. doi: 10.1038/ajg.2010.81.
    1. Lodrup A. B., Reimer C., Bytzer P. Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment. Scandinavian Journal of Gastroenterology. 2013;48(5):515–522. doi: 10.3109/00365521.2012.746395.
    1. Murie J., Allen J., Simmonds R., de Wet C. Glad you brought it up: a patient-centred programme to reduce proton-pump inhibitor prescribing in general medical practice. Quality in Primary Care. 2012;20(2):141–148.
    1. Krol N., Wensing M., Haaijer-Ruskamp F., et al. Patient-directed strategy to reduce prescribing for patients with dyspepsia in general practice: a randomized trial. Alimentary Pharmacology and Therapeutics. 2004;19(8):917–922. doi: 10.1111/j.1365-2036.2004.01928.x.
    1. Lind T., Havelund T., Lundell L., et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis—a placebo-controlled randomized trial. Alimentary Pharmacology and Therapeutics. 1999;13(7):907–914. doi: 10.1046/j.1365-2036.1999.00564.x.
    1. Hróbjartsson A., Gøtzsche P. C. Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. Journal of Internal Medicine. 2004;256(2):91–100. doi: 10.1111/j.1365-2796.2004.01355.x.
    1. Kaptchuk T. J., Kelley J. M., Conboy L. A., et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. British Medical Journal. 2008;336(7651):999–1003. doi: 10.1136/bmj.39524.439618.25.
    1. Johnston B. T., Gunning J., Lewis S. A. Health care seeking by heartburn sufferers is associated with psychosocial factors. The American Journal of Gastroenterology. 1996;91(12):2500–2504.
    1. Yang Y.-X., Lewis J. D., Epstein S., Metz D. C. Long-term proton pump inhibitor therapy and risk of hip fracture. Journal of the American Medical Association. 2006;296(24):2947–2953. doi: 10.1001/jama.296.24.2947.
    1. Laheij R. J. F., Sturkenboom M. C. J. M., Hassing R.-J., Dieleman J., Stricker B. H. C., Jansen J. B. M. J. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. Journal of the American Medical Association. 2004;292(16):1955–1960. doi: 10.1001/jama.292.16.1955.
    1. Dial S., Delaney J. A. C., Barkun A. N., Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. Journal of the American Medical Association. 2005;294(23):2989–2995. doi: 10.1001/jama.294.23.2989.
    1. Moayyedi P., Leontiadis G. I. The risks of PPI therapy. Nature Reviews Gastroenterology and Hepatology. 2012;9(3):132–139. doi: 10.1038/nrgastro.2011.272.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren